Article Information
History
- June 8, 2020.
Article Versions
- Version 1 (May 18, 2020 - 10:19).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Etienne Brochota,b,*,
- Baptiste Demeya,b,
- Antoine Touzéc,
- Sandrine Belouzardd,
- Jean Dubuissond,
- Jean-Luc Schmita,b,
- Gilles Duverliea,b,
- Catherine Francoisa,b,
- Sandrine Castelaina,b and
- Francois Helleb,*
- aDepartment of Virology, Amiens University Medical Center, Amiens, France.
- bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
- cISP1282 INRA University of Tours, Tours, France.
- dUniversité Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
- ↵*Corresponding authors:
Dr Francois Helle, UR-UPJV 4294, Agents Infectieux, Résistance et Chimiothérapie Centre Universitaire de Recherche en Santé, 30 Avenue de la Croix Jourdain, 80000 Amiens, France, Phone: +33-322-825-351, E-mail: francois.helle{at}u-picardie.fr, Dr Etienne Brochot, Laboratoire de Virologie, Centre de Biologie Humaine - CHU Amiens, F-80054 Amiens cedex 1, France, Phone: +33-322-080-764, Fax: +33-322-087-009, E-mail: etienne.brochot{at}u-picardie.fr
Posted June 08, 2020.
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
